AstraZeneca
AZN
$71.10
Share price
0.18%
Change (1 day)
-10.35%
Change (1 year)
Categories
Revenue for AstraZeneca (AZN)
Revenue in 2025 (TTM): $54.98 Billion USD
According to AstraZeneca's latest financial reports the company's current revenue (TTM 
) is $54.98 Billion USD. In 2024 the company made a revenue of $54.07 Billion USD an increase over the revenue in the year 2023 that were of $45.81 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AstraZeneca from 1996 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | $54.98 B | 1.68% |
| 2024 | $54.07 B | 18.03% |
| 2023 | $45.81 B | 3.29% |
| 2022 | $44.35 B | 18.53% |
| 2021 | $37.41 B | 40.58% |
| 2020 | $26.61 B | 9.16% |
| 2019 | $24.38 B | 10.38% |
| 2018 | $22.09 B | -1.67% |
| 2017 | $22.46 B | -2.33% |
| 2016 | $23.00 B | -6.9% |
| 2015 | $24.70 B | -6.81% |
| 2014 | $26.51 B | 3.12% |
| 2013 | $25.71 B | -8.09% |
| 2012 | $27.97 B | -16.72% |
| 2011 | $33.59 B | 0.97% |
| 2010 | $33.26 B | 1.42% |
| 2009 | $32.80 B | 3.81% |
| 2008 | $31.60 B | 6.91% |
| 2007 | $29.55 B | 11.65% |
| 2006 | $26.47 B | 10.54% |
| 2005 | $23.95 B | 11.78% |
| 2004 | $21.42 B | 13.67% |
| 2003 | $18.84 B | 6.82% |
| 2002 | $17.64 B | -25.02% |
| 2001 | $23.53 B | 29.9% |
| 2000 | $18.11 B | -1.74% |
| 1999 | $18.43 B | 87.63% |
| 1998 | $9.82 B | 9.72% |
| 1997 | $8.95 B | -21.63% |
| 1996 | $11.42 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Bristol-Myers Squibb BMY | $47.63 B | -13.36% | 🇺🇸 USA |
 Pfizer PFE | $62.46 B | 13.61% | 🇺🇸 USA |
 Merck MRK | $63.92 B | 16.26% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $40.60 B | -26.14% | 🇬🇧 UK |
 Sanofi SNY | $47.43 B | -13.73% | 🇫🇷 France |
 Eli Lilly LLY | $49.00 B | -10.87% | 🇺🇸 USA |
 Johnson & Johnson JNJ | $89.33 B | 62.47% | 🇺🇸 USA |
 Abbott Laboratories ABT | $42.34 B | -22.99% | 🇺🇸 USA |
 Biogen BIIB | $9.81 B | -82.15% | 🇺🇸 USA |
 Novartis NVS | $53.22 B | -3.20% | 🇨🇭 Switzerland |